AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Aspire Biopharma Holdings, Inc.

$9.06 -$155.34 (-94.49%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$9.12
Day Range
$9.06$9.38
Year Range
$0.11$18.76
Market Cap
1.05M
AVG Volume
660.57K
Trailing/Forward PE
-1.13/-
PEG ratio
-0.01
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
025K50K75K100K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q297.66K
26 Q134.55K
25 Q46.2K
25 Q31.94K
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-11.05M
26 Q1-11.76M
25 Q4-24.48M
25 Q3-28.7M
25 Q2-27.39M
25 Q1-26.01M
24 Q4-12.54M
24 Q3-3.76M
24 Q2-3.29M
24 Q1-875.26K
Operating Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-7.09M
26 Q1-5.44M
25 Q4-19.35M
25 Q3-18.14M
25 Q2-17.21M
25 Q1-16.91M
24 Q4-3.88M
24 Q3-3.64M
24 Q2-3.75M
24 Q1-3.54M
EBITDA (USD) · TTM
-30M-20M-10M010M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q23.29M
26 Q14.28M
25 Q4-11.31M
25 Q3-24.09M
25 Q2-26.37M
25 Q1-25.32M
24 Q4-11.95M
24 Q3-3.45M
24 Q2-2.82M
24 Q1-2.43M
Cash Flows (USD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-7.19M
26 Q1-6.21M
25 Q4-4.92M
25 Q3-3.52M
25 Q2-2.39M
25 Q1-1.84M
24 Q4-2.35M
24 Q3-2.98M
24 Q2-3.13M
24 Q1-2.73M
EPS (USD) · TTM
-40-30-20-10024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-8.02
26 Q1-8.41
25 Q4-23.08
25 Q3-32.87
25 Q2-32.16
25 Q1-31.42
24 Q4-18.17
24 Q3-5.47
24 Q2-4.8
24 Q1-1.65
Expenses (USD) · TTM
-5M05M10M15M20MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q27.07M
26 Q15.45M
25 Q419.35M
25 Q318.18M
25 Q217.68M
25 Q117.39M
24 Q44.35M
24 Q34.07M
24 Q23.69M
24 Q13.47M
Shares Outstanding (USD) · TTM
-100M0100M200M300MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ASBP Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-157.5K
26 Q1-13.41K
25 Q4-14.13M
25 Q3-14.13M
25 Q2-27.91M
25 Q1-14.13M
24 Q40
24 Q3-917.25K
24 Q213.5M
24 Q1284M
Employee Count
02K4K6K2024
ASBP Employee Count by quarter
PeriodEmployee Count
20245K
PE Ratio
0200000400000600000800000med 1894.6Oct 22Jan 23May 23Aug 23Nov 23Feb 24May 24
ASBP PE Ratio by quarter
PeriodPE Ratio
May 241925.41
May 242010.98
May 242053.77
May 241921.98
May 241913.94
Apr 241908.29
Apr 241903.16
Apr 241901.45
Apr 241894.6
Mar 241885.19
Mar 241885.19
Mar 241882.62
Mar 241233.32
Mar 241229.97
Feb 241229.97
Feb 241227.73
Feb 241219.92
Feb 241217.69
Jan 241222.15
Jan 241222.15
Jan 241217.69
Jan 241214.34
Dec 231215.46
Dec 231263.45
Dec 231214.34
Dec 231213.23
Dec 231212.11
Nov 231210.99
Nov 231212.11
Nov 231212.11
Nov 231300.49
Oct 231293.93
Oct 231386.31
Oct 231364.86
Oct 231264.73
Sep 231290.95
Sep 231345.79
Sep 231311.22
Sep 231305.85
Sep 231305.26
Aug 231293.34
Aug 231308.83
Aug 231311.22
Aug 231824.34
Jul 231796.96
Jul 231796.96
Jul 231795.59
Jul 231790.12
Jun 231783.27
Jun 231783.27
Jun 231788.4
Jun 231778.14
Jun 231779.85
May 231778.14
May 231771.29
May 231800.38
May 233399.13
Apr 233394.29
Apr 233395.9
Apr 233393.32
Apr 233389.45
Mar 233389.45
Mar 233379.76
Mar 2310167.76
Mar 2310167.76
Mar 2310159.01
Feb 2310148.32
Feb 2310128.87
Feb 2310119.15
Feb 2310119.15
Jan 2310099.71
Jan 2310089.99
Jan 2310051.11
Jan 2310031.67
Dec 2210012.23
Dec 2210021.95
Dec 2210012.23
Dec 229973.34
Dec 229963.62
Nov 229949.04
Nov 229939.32
Nov 229919.88
Nov 22653535.12
Oct 22652893.45
Oct 22651930.95
Oct 22648080.97
Oct 22648080.97
Sep 22650647.63
Sep 22648722.63
Sep 22648080.97
Sep 22647118.47
Sep 22646797.64
Aug 22646155.98
Aug 22644872.65
Aug 22645514.31
Free Cash Flow Yield
-100%-75%-50%-25%0%med -0.62%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ASBP Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-76.42%
Sep 26-78.06%
Aug 26-81.36%
Aug 26-86.87%
Aug 26-88.2%
Aug 26-53.74%
Jul 26-63.72%
Jul 26-57.22%
Jul 26-66.58%
Jul 26-69.12%
Jul 26-66.9%
Jun 26-69.24%
Jun 26-63.14%
Jun 26-83.76%
Jun 26-77.8%
May 26-75.67%
May 26-76.79%
May 26-74.05%
May 26-59.34%
May 26-51.7%
Apr 26-53.55%
Apr 26-40.71%
Apr 26-10.36%
Apr 26-10.76%
Mar 26-10.36%
Mar 26-13.18%
Mar 26-9.02%
Mar 26-8.16%
Feb 26-6.81%
Feb 26-6.62%
Feb 26-6.62%
Feb 26-6.48%
Jan 26-4.44%
Jan 26-5.01%
Jan 26-4.28%
Jan 26-2.28%
Jan 26-1.73%
Dec 25-2.19%
Dec 25-2.41%
Dec 25-2.49%
Dec 25-2.57%
Nov 25-2.23%
Nov 25-2.44%
Nov 25-2.23%
Nov 25-0.67%
Oct 25-0.42%
Oct 25-0.47%
Oct 25-0.47%
Oct 25-0.49%
Oct 25-0.42%
Sep 25-0.45%
Sep 25-0.39%
Sep 25-0.38%
Sep 25-0.31%
Aug 25-0.28%
Aug 25-0.3%
Aug 25-0.45%
Aug 25-0.48%
Aug 25-0.45%
Jul 25-0.32%
Jul 25-0.45%
Jul 25-0.49%
Jul 25-0.55%
Jun 25-0.57%
Jun 25-0.56%
Jun 25-0.44%
Jun 25-0.42%
May 25-0.38%
May 25-0.72%
May 25-0.65%
May 25-0.79%
May 25-0.83%
Apr 25-0.58%
Apr 25-0.5%
Apr 25-0.48%
Apr 25-0.8%
Mar 25-0.56%
Mar 25-0.57%
Mar 25-0.58%
Mar 25-0.42%
Feb 25-0.24%
Feb 25-0.14%
Feb 25-0.04%
Feb 25-0.03%
Jan 25-0.03%
Jan 25-0.03%
Jan 25-0.03%
Jan 25-0.03%
Jan 25-0.03%
Dec 24-0.03%
Dec 24-0.03%
Dec 24-0.03%
Dec 24-0.03%
Nov 24-0.03%
Nov 24-0.03%
Nov 24-0.03%
Nov 24-0.03%
Nov 24-0.03%
Oct 24-0.03%
Oct 24-0.03%
Price to Sales
050000100000150000med 4663Nov 25Jan 26Feb 26Apr 26Jun 26Jul 26Sep 26
ASBP Price to Sales by quarter
PeriodPrice to Sales
Sep 2696.29
Sep 2694.27
Aug 2690.44
Aug 2684.7
Aug 2683.43
Aug 26334.42
Jul 26282.08
Jul 26314.09
Jul 26269.96
Jul 26260.01
Jul 26268.66
Jun 26259.58
Jun 26284.67
Jun 26214.58
Jun 26231.02
May 26237.51
May 26234.05
May 26242.71
May 261337.8
May 261535.45
Apr 261482.42
Apr 261950.05
Apr 267665.2
Apr 267375.95
Mar 2617478.25
Mar 2613740.2
Mar 2620093.61
Mar 2622198.65
Feb 2626600.11
Feb 2627365.58
Feb 2627365.58
Feb 2627939.68
Jan 2640761.32
Jan 2636168.49
Jan 2642292.26
Jan 2679608.96
Jan 26104869.5
Dec 2582670.85
Dec 2575016.14
Dec 2572719.72
Dec 2570423.31
Nov 2581139.9
Nov 2574250.67
Nov 2581139.9
EV/EBITDA
-20000200040006000med 1914.81May 23Aug 23Nov 23Jan 24Apr 24Jun 26Sep 26
ASBP EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 26-0.84
Sep 26-0.9
Aug 26-1.01
Aug 26-1.18
Aug 26-1.22
Aug 261.68
Jul 261.26
Jul 261.52
Jul 261.16
Jul 261.08
Jul 261.15
Jun 261.08
Jun 261.28
Jun 260.71
Jun 260.85
May 260.9
May 260.87
May 260.94
May 242813.63
May 242938.68
May 243001.2
May 242808.63
May 242796.87
Apr 242788.62
Apr 242781.12
Apr 242778.62
Apr 242768.61
Mar 242754.86
Mar 242754.86
Mar 242751.1
Mar 241555.59
Mar 241551.37
Feb 241551.37
Feb 241548.55
Feb 241538.7
Feb 241535.88
Jan 241541.51
Jan 241541.51
Jan 241535.88
Jan 241531.66
Dec 231533.06
Dec 231593.6
Dec 231531.66
Dec 231530.25
Dec 231528.84
Nov 231527.43
Nov 231528.84
Nov 231528.84
Nov 231914.81
Oct 231905.15
Oct 232041.18
Oct 232009.58
Oct 231862.15
Sep 231900.77
Sep 231981.5
Sep 231930.6
Sep 231922.7
Sep 231921.83
Aug 231904.28
Aug 231927.09
Aug 231930.6
Aug 232117.72
Jul 232085.94
Jul 232085.94
Jul 232084.35
Jul 232077.99
Jun 232070.04
Jun 232070.04
Jun 232076
Jun 232064.08
Jun 232066.07
May 232064.08
May 232056.14
May 232089.91
May 235089.59
Apr 235082.34
Apr 235084.76
Apr 235080.89
Apr 235075.09
Mar 235075.09
Mar 235060.59
Price/Operating Cashflow
60400606006080061000med 60731.36Apr 22Apr 22Apr 22May 22May 22
ASBP Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
May 2260548.8
May 2260731.36
Apr 2260731.36
Apr 2260974.77
Apr 2260853.07
Price to Book
050000100000150000med 509.27Nov 23Mar 24Jun 24Sep 24Jan 25May 26Sep 26
ASBP Price to Book by quarter
PeriodPrice to Book
Sep 260.8
Sep 260.78
Aug 260.75
Aug 260.7
Aug 260.69
Aug 262.99
Jul 262.52
Jul 262.81
Jul 262.41
Jul 262.32
Jul 262.4
Jun 262.32
Jun 262.54
Jun 261.92
Jun 262.06
May 262.12
May 262.09
May 262.17
Apr 254136.37
Mar 255869.79
Mar 255778.07
Mar 255686.36
Mar 257887.53
Feb 2513757.32
Feb 2523479.15
Feb 2584745.06
Feb 25104280.45
Jan 25118679.77
Jan 25111067.39
Jan 25105160.92
Jan 25104830.74
Jan 25104647.31
Dec 24105472.75
Dec 24105472.75
Dec 24104830.74
Dec 24104830.74
Nov 24105426.89
Nov 24105426.89
Nov 24106325.7
Nov 2415311.99
Nov 2415061.19
Oct 2415430.79
Oct 2415470.39
Oct 2415113.99
Oct 2416381.19
Sep 2415298.79
Sep 2415298.79
Sep 2415219.59
Sep 2414823.59
Aug 2414823.59
Aug 2414823.59
Aug 2414823.59
Aug 24534.45
Aug 24530.21
Jul 24530.21
Jul 24530.21
Jul 24530.21
Jul 24530.21
Jun 24531.15
Jun 24540.11
Jun 24530.68
Jun 24537.28
May 24438.96
May 24458.47
May 24468.23
May 24438.18
May 24436.35
Apr 24435.06
Apr 24433.89
Apr 24433.5
Apr 24431.94
Mar 24429.8
Mar 24429.8
Mar 24429.21
Mar 24431.19
Mar 24430.02
Feb 24430.02
Feb 24429.24
Feb 24426.51
Feb 24425.73
Jan 24427.29
Jan 24427.29
Jan 24425.73
Jan 24424.56
Dec 23424.95
Dec 23441.73
Dec 23424.56
Dec 23424.17
Dec 23423.78
Nov 23423.39
Nov 23423.78
Nov 23423.78
Nov 23512.44
Oct 23509.86
Oct 23546.26
Oct 23537.81
Oct 23498.35
Sep 23508.68
Sep 23530.29
Sep 23516.67
Aspire Biopharma Holdings, Inc.
ASBP
Stockpicker

Video analysis: ASBP

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ASBP

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

accessnewswire.com · 9 Sep 2026

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Brings total authorized repurchase to $10 million Reflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunity Increased authorization supported by strength of newly acquired Dura Control Systems Corp's (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.3 million and approximately $103.9 million and Adjusted EBITDA1 of $10.5 million, respectively ESTERO, FL / ACCESS Newswire / September 9, 2026 / Aspire-Lakewood Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced the Board authorized a $10 million common stock repurchase program (the "Stock Repurchase Program"). This expanded share repurchase program is effective September 9, 2026.

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

accessnewswire.com · 8 Sep 2026

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc." to "Aspire-Lakewood Holdings, Inc." The name change is effective upon the filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company's ticker symbol, "ASBP", will remain unchanged.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

accessnewswire.com · 13 Aug 2026

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems, a leading global automotive supplier with a 100+ year history and $200M+ in 2025 revenue.

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

accessnewswire.com · 10 Aug 2026

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business Expected to immediately improve path to profitability ESTERO, FL / ACCESS Newswire / August 10, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that, the Company has completed its previously announced acquisition (the "Acquisition") of Dura Driver Control Systems ("DCS"), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire's ability to deliver increased revenues, durable earnings and cash flow, driven by a new portfolio of product offerings in the large and growing markets for vehicle and mobility control systems.

Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9%  – Time to Buy?

defenseworld.net · 4 Aug 2026

Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?

Shares of Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP - Get Free Report) rose 10.9% on Monday. The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares changed hands during trading, a decline of 49% from the average daily volume of 54,125 shares. The stock had previously closed at $6.52. Wall Street

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

accessnewswire.com · 20 Jul 2026

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMB™ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMB™'s commitment to delivering fast-acting energy to elite athletes and active consumers worldwide.

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

accessnewswire.com · 24 Jun 2026

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

globenewswire.com · 17 Jun 2026

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.'s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.